SCHEMBL23928149

SCHEMBL23928149

O=C(O)NCCc1ccc(NC(=O)CCN2CCOCC2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.67
CYP2C19 P33261 1/20 0.67
ATM Q13315 1/20 0.64
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
CA9 Q16790 2/20 0.59
RAB9A P51151 2/20 0.57
EPHX2 P34913 1/20 0.57
TSHR P16473 2/20 0.56
HTT P42858 2/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
MAPT P10636 2/20 0.54
TERT O14746 1/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52
HDAC10 Q969S8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23291148 0.89 ALDH1A1 (0.63) LMNAATMEPHX2TSHRALOX15
SCHEMBL23291332 0.84 ATM (0.68) LMNACYP2C19ATMCA1CA2
SCHEMBL23291259 0.84 CD274 (0.56) LMNACYP2C19ATMCA1CA2
SCHEMBL13102349 0.81 ATM (0.75) LMNACYP2C19ATMCA1CA2
SCHEMBL13118343 0.81 LMNA (1.00) LMNACYP2C19ATMCA1CA2
SCHEMBL15437067 0.78 ATM (0.75) LMNACYP2C19ATMCA1CA2
SCHEMBL4749808 0.78 ATM (0.75) LMNACYP2C19ATMCA1CA2
SCHEMBL23928240 0.77 LTA4H (0.60) CA1CA2CA9RAB9AEPHX2
SCHEMBL4741236 0.77 CYP2C19 (0.60) CYP2C19TSHRMAPTSMN1; SMN2
SCHEMBL23291288 0.76 EPHX2 (0.60) LMNAEPHX2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 LMNA 3595/4885CYP2C19 832/4885ATM 1124/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 LMNA 3595/4885CYP2C19 832/4885ATM 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.